RATIONALE: The antidepressant response exhibits a characteristic delay. BALB/cJ mice respond to chronic, but not subchronic, treatment with selective serotonin reuptake inhibitors (SSRIs), providing a model of antidepressant onset. Identification of other mouse strains exhibiting this phenotype will provide additional tools for studying mechanisms of the antidepressant response. OBJECTIVES: We aimed to identify inbred mouse strains that respond to chronic, but not subchronic, SSRI treatment in the forced swim test (FST). We also assessed whether response correlated with genotype at the functional C1473G polymorphism in tryptophan hydroxylase-2 (Tph2). METHODS: BALB/cJ, three closely related strains (BALB/cByJ, SEA/GnJ, A/J), and four distantly related strains (C57BL/6J, C57BL/10J, CAST/EiJ, SM/J) received the SSRI citalopram (0-30 mg/kg/day in drinking water) for ~4 weeks and were assessed for locomotion and FST behavior. Citalopram-responsive strains were assessed identically following ~1 week of treatment. C1473G genotypes were determined. RESULTS: BALB/cJ and related strains carried the 1473G allele and responded to chronic citalopram treatment in the FST. BALB/cJ, BALB/cByJ, and SEA/GnJ mice showed either no response or an attenuated response to subchronic treatment. Distantly related strains carried the 1473C allele and showed no response to citalopram. No relationship was found between the antidepressant response and baseline immobility or locomotion. CONCLUSIONS: BALB/cJ and related strains exhibit an antidepressant response to chronic SSRI treatment that emerges over time and is likely a heritable trait. This antidepressant response is associated with carrying the 1473G allele in Tph2. In conclusion, BALB/cJ and related strains provide valuable models for studying the therapeutic mechanisms of SSRIs.
RATIONALE: The antidepressant response exhibits a characteristic delay. BALB/cJ mice respond to chronic, but not subchronic, treatment with selective serotonin reuptake inhibitors (SSRIs), providing a model of antidepressant onset. Identification of other mouse strains exhibiting this phenotype will provide additional tools for studying mechanisms of the antidepressant response. OBJECTIVES: We aimed to identify inbred mouse strains that respond to chronic, but not subchronic, SSRI treatment in the forced swim test (FST). We also assessed whether response correlated with genotype at the functional C1473G polymorphism in tryptophan hydroxylase-2 (Tph2). METHODS: BALB/cJ, three closely related strains (BALB/cByJ, SEA/GnJ, A/J), and four distantly related strains (C57BL/6J, C57BL/10J, CAST/EiJ, SM/J) received the SSRI citalopram (0-30 mg/kg/day in drinking water) for ~4 weeks and were assessed for locomotion and FST behavior. Citalopram-responsive strains were assessed identically following ~1 week of treatment. C1473G genotypes were determined. RESULTS: BALB/cJ and related strains carried the 1473G allele and responded to chronic citalopram treatment in the FST. BALB/cJ, BALB/cByJ, and SEA/GnJ mice showed either no response or an attenuated response to subchronic treatment. Distantly related strains carried the 1473C allele and showed no response to citalopram. No relationship was found between the antidepressant response and baseline immobility or locomotion. CONCLUSIONS: BALB/cJ and related strains exhibit an antidepressant response to chronic SSRI treatment that emerges over time and is likely a heritable trait. This antidepressant response is associated with carrying the 1473G allele in Tph2. In conclusion, BALB/cJ and related strains provide valuable models for studying the therapeutic mechanisms of SSRIs.
Authors: Kjell Erlandsson; Tharani Sivananthan; Dominic Lui; Andrea Spezzi; Caroline E Townsend; Song Mu; Richard Lucas; Steven Warrington; Peter J Ell Journal: Eur J Nucl Med Mol Imaging Date: 2005-08-26 Impact factor: 9.236
Authors: Adem Can; David T Dao; Michal Arad; Chantelle E Terrillion; Sean C Piantadosi; Todd D Gould Journal: J Vis Exp Date: 2012-01-29 Impact factor: 1.355
Authors: Christian Perez; Amanda M Barkley-Levenson; Benjamin L Dick; Peter F Glatt; Yadira Martinez; Dionicio Siegel; Jeremiah D Momper; Abraham A Palmer; Seth M Cohen Journal: J Med Chem Date: 2019-01-31 Impact factor: 7.446
Authors: Laura J Sittig; Choongwon Jeong; Emily Tixier; Joe Davis; Camila M Barrios-Camacho; Abraham A Palmer Journal: Mamm Genome Date: 2014-07-05 Impact factor: 2.957
Authors: Elyse C Dankoski; Kara L Agster; Megan E Fox; Sheryl S Moy; R Mark Wightman Journal: Neuropsychopharmacology Date: 2014-07-01 Impact factor: 7.853
Authors: M D Opal; S C Klenotich; M Morais; J Bessa; J Winkle; D Doukas; L J Kay; N Sousa; S M Dulawa Journal: Mol Psychiatry Date: 2013-10-29 Impact factor: 15.992
Authors: Emily Durham; Serena Jen; Lin Wang; Joseph Nasworthy; Mohammed Elsalanty; Seth Weinberg; Jack Yu; James Cray Journal: PLoS One Date: 2015-10-02 Impact factor: 3.240